News

News 10.05.2024 SCHLIEREN, ZURICH, SWITZERLAND, May 9, 2024 /EINPresswire.com/ -- Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced the nomination of an anti-allergen multispecific antibody that is undergoing Investigative New Drug (IND)-enabling studies and subsequent clinical development for the treatment of peanut allergy. For the...

News 07.05.2024 Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised...

News 30.04.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a comprehensive, peer-reviewed publication of preclinical data supporting MP0533’s proposed unique mechanism of action (MoA)...

News 24.04.2024 Schlieren (Zurich), Switzerland, April 24, 2024 – Kuros Biosciences (“Kuros”), a leader in advanced bone healing technologies, today announced its financial performance for the first quarter of 2024. Direct sales of MagnetOs rose 155% in the first three months of 2024, to CHF 13.9 million from CHF 5.4 million, compared...

News 23.04.2024 Zürich, April 22, 2024 In a notable collaboration that underscores the power of innovation in drug discovery, SanaGen and InSphero, alongside the renowned Sanquin research institute, have been awarded a 1.3 million euro grant for the ambitious project NOCAAVAAT. The NOCAAVAAT project, which aims to develop a breakthrough gene therapy for severe Alpha-1 anti-Trypsin (AAT)...